OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

2025-522659-24-00 · tracked via the Priya Life Science EU tracker

Sponsor

Leids Universitair Medisch Centrum (LUMC)

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Neoplasms

Decision date

03/12/2025

Enrollment target

Sites

Netherlands

Condition studied

Ovarian carcinoma

Investigational medicinal product(s)

ALDESLEUKINTIL cells

Eligibility

Age group

65+ years, 18-64 years

Sex

Female

Primary endpoint

mmunotherapy related grade III/IV NCI-CTC toxicity

Endpoint detail

All grade NCI CTC toxicity, CD8/CD4/MDSC, M1/2, Treg

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522659-24-00 on CTIS ↗ ← All trials in the EU